Less Glycemic Variability, Better Patient
Reported Outcomes with Lantus and Apidra
vs. Premix Analog Insulin
- Study Findings Presented at American Diabetes Association’s 70
Annual Scientific Sessions -
Paris, France – June 26, 2010 – Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today results of a
study which demonstrated that patients using Lantus (insulin glargine [rDNA origin] injection) once-daily and Apidra
(insulin glulisine [rDNA origin] injection) before meals reported improved patient reported outcomes and decreased
glycemic variability versus premix analog insulin. Two abstracts from this study were highlighted at the American
Diabetes Association’s 70 Annual Scientific Sessions (ADA).
People following a basal-bolus insulin regimen use separate injections of a basal insulin and a mealtime insulin. This
regimen is designed to address hyperglycemia before it happens by providing adequate insulin to cover fasting and
prandial insulin needs. A premix insulin regimen combines prandial insulin analogs and the intermediate-acting
insulin, NPH, in one injection. The results of this study demonstrated that patients using a basal-bolus regimen, with
Lantus and Apidra , reported improved outcomes and quality of life.
“These results indicate that patients treated with a basal-bolus insulin regimen consisting of Lantus and Apidra
demonstrate an improved quality of life and patient reported outcomes compared to those treated with premix analog
insulin,” said Donald Simonson, MD, MPH, ScD of the Endocrinology, Diabetes and Hypertension Division of Brigham
and Women’s Hospital in Boston, Massachusetts and principal investigator of the study.
About study results
In this multicenter, randomized clinical trial conducted in 52 US centers, 388 insulin treated patients (82 Type 1
diabetes, 306 Type 2 diabetes) were randomized to open-label daily Lantus and premeal Apidra (Lantus and
Apidra ; n=192) or twice-daily premix 75/25 or 70/30 (premix; n=196) for 12 weeks (Period